2024 Phesgo label

Phesgo label

Author: sjtt

August undefined, 2024

WebNov 16, 2024 · Phesgo Dosage Generic name: PERTUZUMAB 1200mg in 15mL, TRASTUZUMAB 600mg in 15mL, HYALURONIDASE (HUMAN RECOMBINANT) 30000U in 15mL Dosage form: injection, solution Drug class: HER2 inhibitors Medically reviewed by Drugs.com. Last updated on Nov 16, 2024. Patient Selection WebPHESGO demonstrated non-inferior PK vs IV PERJETA ® (pertuzumab) + trastuzumab 1 FeDeriCa trial overview 1,2 Phase III, randomized, open-label non-inferiority trial conducted in 500 patients with operable or locally advanced (including inflammatory) HER2+ early breast cancer (with tumor size >2 cm or node-positive)

FDA Approves Breast Cancer Treatment That Can Be Administered At …

WebBrief Summary: This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer … WebOct 13, 2024 · DESCRIPTION. PHESGO is a combination of pertuzumab, trastuzumab, and hyaluronidase. Pertuzumab is a recombinant humanized monoclonal antibody that … hockey club ajoie

Genentech: Press Releases Monday, Jun 29, 2024

WebJan 1, 2024 · Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. References 1. Phesgo [package insert]. South San Francisco, CA; Genentech, Inc; June 2024. Accessed August 2024. 2. Weba phase iii, randomized, open-label study evaluating the efficacy and safety of giredestrant in combination with phesgo versus phesgo after induction therapy with phesgo + taxane in patients with previously untreated her2-positive, estrogen receptor-positive locally-advanced or metastatic breast cancer WebPhesgo is given by a healthcare provider as an injection under the skin on the thigh. After the first dose, it’s given once every 3 weeks. For the first dose, you’ll get 1,200 mg of … hockey clothing sale

Phesgo: Package Insert / Prescribing Information

Food and Drug Administration

WebJun 29, 2024 · SAN DIEGO, June 29, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab,... Web- The clinical development program for Phesgo consisted of a pivotal clinical study: (WO40324 – FeDeriCa), the study assesed the efficacy and saftey of the product. Summary of the clinical studies presented hereafter: - WO40324 – FeDeriCa FeDeriCa is an ongoing pivotal phase III, two-arm, open-label randomised study investigating hockey clothing ukWebPertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast cancer that has spread … ht6cb-240

"WebPHESGO may cause administration-related reactions: PHESGO is given as an injection. The active ingredients in PHESGO have been associated with severe administration reactions, … " - Phesgo label

Phesgo label

WebMar 18, 2024 · Phesgo 600 mg/600 mg solution for injection Active Ingredient: trastuzumab, pertuzumab Company: Roche Products Limited See contact details ATC code: L01XY02 About Medicine Prescription only medicine Healthcare Professionals (SmPC) Patient Leaflet (PIL) This information is for use by healthcare professionals Last updated on emc: 18 Mar … WebJun 29, 2024 · The FDA has granted approval to phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase-zzxf – for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early-stage disease. 1 Patients should be …

Did you know?

Weblabel clinical trial periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved. WebJun 29, 2024 · Phesgo is initially used in combination with chemotherapy and could continue to be administered at home by a qualified health care professional once the …

WebPhesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received … WebPhase III, randomized, open-label trial designed to demonstrate non-inferiority of PHESGO compared to IV PERJETA and trastuzumab. The trial was conducted in 500 patients with operable or locally advanced (including inflammatory) HER2+ …

WebPhesgo is supplied as: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15mL (80 mg, 40 mg, and 2,000 units/mL) of solution in a single-dose vial. 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL (60 mg, 60 mg, and 2,000 units/mL) of solution in a single-dose vial WebPHESGO on Day 1 of the first taxane-containing cycle [see Clinical Studies (14.2)]. Metastatic Breast Cancer (MBC) When administered with PHESGO, the recommended …

WebIndications. Early Breast Cancer PHESGO TM (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for. the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part …

WebPhesgo Product Label. The following document was submitted to the FDA by the labeler of this product Genentech, Inc.. The document includes published materials associated … ht6f1800b transmitter batteryWebPHESGO is supplied in sterile, preservative-free, single-dose vials for subcutaneous administration. Store PHESGO vials in the refrigerator at 2°C to 8°C (36°F to 46°F) in the … ht6z0ac_ht7a0acWebJan 1, 2024 · for PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Breast Cancer The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for PHESGO effective January 1, 2024. TYPE CODE DESCRIPTION Diagnosis: ICD-10-CM C50.011–C50.019 C50.111–C50.119 C50.211–C50.219 C50.311–C50.319 … ht6f1800bWebPHESGO should be administered every 3 weeks 1,2 Loading (initial) dose 1200 mg pertuzumab, 600 mg trastuzumab, 30,000 units hyaluronidase per 15 mL supplied in a single-dose, ready-to-use vial Administer subcutaneously over approximately 8 minutes at a rate of no more than 2 mL/min hockey club 74WebPHESGO has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone. Do … ht6yfWebPolicy. Precertification of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) is required of all Aetna participating providers and members in applicable plan designs. For … ht6f8WebJul 5, 2024 · Phesgo combines pertuzumab, trastuzumab, and hyaluronidase-zzxf. The new formulation is a subcutaneous injection rather than an infusion. It can be administered in a home setting in less time... ht6s-10cuy